GlobeNewswire Inc.··Researchandmarkets.ComArgenx's Vyvgart Poised for Explosive Growth as Autoimmune Market Expands
Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.
ARGXFUJIYVYVGARTbiologic therapy